Related Experiment Video

Updated: May 4, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

913

Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer

Miriam Kim1, Surbhi Agarwal, Debu Tripathy

  • 1aUniversity of Southern California bKeck School of Medicine cUSC/Norris Comprehensive Cancer and Department of Medicine, Los Angeles, California, USA.

Current Opinion in Obstetrics & Gynecology
|December 17, 2013
PubMed
Abstract

Insights

Novel HER2-targeting agents have significantly improved survival for HER2-positive breast cancer. These advancements offer better outcomes in both early and advanced stages, though resistance remains a challenge.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • HER2-positive breast cancer is an aggressive subtype.
  • The HER2 receptor pathway is a key driver of tumor growth and aggressiveness.
  • Trastuzumab has previously altered the natural history of this disease.

Purpose of the Study:

  • To review recent developments in HER2-positive breast cancer treatment.
  • To focus on novel HER2-targeting agents and combinations.
  • To highlight improvements in clinical outcomes.

Main Methods:

  • Review of recent clinical studies and approvals.
  • Analysis of survival data with new HER2-targeted agents.
  • Examination of resistance mechanisms and biomarkers.

Main Results:

  • New agents like pertuzumab and ado-trastuzumab emtansine (T-DM1) improve survival in advanced HER2-positive breast cancer.
  • These agents demonstrate improved survival without increased toxicity.
  • Resistance to HER2-targeted therapies is a significant clinical challenge.

Conclusions:

  • HER2-targeted therapies, often combined with chemotherapy, are standard of care.
  • These treatments improve cure rates in early-stage disease and prolong survival in advanced disease.
  • Understanding resistance mechanisms is crucial for individualizing future therapies.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81